ReviewJournal of orthopaedic surgery and research2026
Application of bupivacaine liposomes for iliac fascia blockade in total hip arthroplasty.
Review in Journal of orthopaedic surgery and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Total hip arthroplasty (THA) is the primary surgical treatment for end-stage hip diseases; however, significant postoperative pain often severely impedes early mobilization and functional recovery. In recent years, the concept of multimodal analgesia has become a consensus in perioperative pain management, aiming to reduce opioid consumption and related complications. Liposomal bupivacaine, as a long-acting sustained-release local anesthetic, provides analgesic effects for up to 72 h following a single injection, offering a new option for postoperative pain control. Leveraging this advantage in combination with the fascia iliaca compartment block (FICB), which provides significant postoperative analgesia, holds promise for further optimizing analgesic strategies and promoting rapid recovery after THA. This article reviews the pharmacological properties of liposomal bupivacaine, the current clinical application status of FICB, and the analgesic efficacy and safety of their combined use in THA, aiming to provide evidence for clinical practice and scientific research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.